Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 14
- Registration Number
- NCT00670800
- Locations
- 🇺🇸
University of Michigan, Michigan Clinical Research Unit, Ann Arbor, Michigan, United States
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 293
- Registration Number
- NCT00669864
Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2009-02-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 28
- Registration Number
- NCT00667498
- Locations
- 🇺🇸
Yale Center for Clinical Investigation (YCCI), New Haven, Connecticut, United States
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 570
- Registration Number
- NCT00661362
- Locations
- 🇰🇷
Research Site, Uijeongbu-si, Korea, Republic of
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1217
- Registration Number
- NCT00660907
- Locations
- 🇬🇧
Research Site, Trowbridge, United Kingdom
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- London Health Sciences Centre
- Target Recruit Count
- 28
- Registration Number
- NCT00659568
- Locations
- 🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
The Copenhagen Insulin and Metformin Therapy Trial
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 415
- Registration Number
- NCT00657943
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰Frederiksberg Hospital, Frederiksberg, Denmark
Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT00647023
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 300
- Registration Number
- NCT00636766
- Locations
- 🇬🇷
General Hospital of Thessaloniki "Hippokratio", Thessaloniki, Greece
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT00631488
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.